GLYC News and Press, GlycoMimetics Inc. From 09/05/23

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live webcast of the presentation will be av...

2023-08-14 08:55:03 ET Summary GlycoMimetics is a biotech focused on developing novel agents that utilize carbohydrate chemistry for therapeutic effect. They have promising mid-stage clinical data and a projected critical data readout in late 2024. Operating costs and funding ...

2023-08-02 13:09:08 ET GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Conference Call August 2, 2023, 08:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - CMO Brian Hahn - CFO Conference Call Partici...

2023-08-02 07:06:55 ET GlycoMimetics press release ( NASDAQ: GLYC ): Q2 Non-GAAP EPS of -$0.13 beats by $0.04 . Cash and cash equivalents as of June 30, 2023 were $58.0 million. For further details see: GlycoMimetics Non-GAAP EPS of -$0.13 beats by $0.04

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 2024 after addition of time-based analysis option U.S. Food and Drug Administration (FDA) agrees to initial Pediatric Study Plan (iPSP) for uproleselan, an...

2023-08-01 13:51:55 ET GlycoMimetics ( NASDAQ: GLYC ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $0.03M. Over the last 3 months, EPS estimates hav...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with...

2023-06-26 10:17:58 ET GlycoMimetics ( NASDAQ: GLYC ) has joined the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023. GLYC is +0.5% to $1.88 Source: Press Release ...

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual rec...

Final analysis to be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date; topline results expected by the end of Q2 2024 Prolonged duration of blinded pooled survival in relapsed/refractory Acute Myeloid Leukemia expected to yield clinically mature dataset in Q2 ...